SecurityERN / Erin Energy Corp. (295625107)
Interim CEO,Gen Counsel,SecMalek Jean-Michel
IndustryDrilling Oil and Gas Wells
Institutional Owners35
Institutional Shares2,421,516 - 1.12%
Common Shares Outstanding215,337,614 shares (as of 2017-12-31)
Institutional Value$ 8,571,000 USD
Related ERINQ / Erin Energy Corp

Institutional Stock Ownership and Shareholders()

ERN / Erin Energy Corp. Institutional Ownership

Erin Energy Corp. (AMEX:ERN) has 35 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,421,516 shares. Largest shareholders include Vanguard Group Inc, BlackRock Fund Advisors, Millennium Management Llc, BlackRock Institutional Trust Company, N.A., BlackRock Inc., Schwab Charles Investment Management Inc, Northern Trust Corp, Barclays Plc, Goldman Sachs Group Inc, and California Public Employees Retirement System.
Erin Energy Corp. (AMEX:ERN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ern"><img src="https://images.fintel.io/us-ern-so.png" alt="ERN / Erin Energy Corp. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-09 13F-HR NORTHERN TRUST CORP 59,392 63,191 6.40 163 230 41.10
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 1,623 1,629 0.37 4 6 50.00
2018-05-14 13F-HR MORGAN STANLEY 29,463 30,757 4.39 81 112 38.27
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 30,000 30,000 0.00 82 109 32.93
2017-02-10 13F-HR BlackRock Investment Management, LLC 51,713 51,713 0.00 122 158 29.51
2018-05-15 13F-HR BARCLAYS PLC 62,484 62,394 -0.14 172 228 32.56
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 53,382 53,382 0.00 147 195 32.65
2018-05-09 13F-HR BlackRock Inc. 89,049 92,409 3.77 244 337 38.11
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 100,962 100,962 0.00 237 308 29.96
2017-02-10 13F-HR BlackRock Advisors LLC 3,671 3,671 0.00 9 11 22.22
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 0 15,522 0 57
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 77,800 82,480 6.02 214 302 41.12
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 5,080 2,724 -46.38 14 10 -28.57
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 36 36 0.00 99 131 32.32
2018-05-15 13F-HR UBS Group AG 49,319 49,817 1.01 136 181 33.09
2018-05-11 13F-HR CITADEL ADVISORS LLC 15,522 57
2017-02-10 13F-HR BlackRock Fund Advisors 420,585 505,545 20.20 988 1,542 56.07
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 31,643 59,025 86.53 87 215 147.13
2018-05-15 13F-HR VANGUARD GROUP INC 572,966 646,784 12.88 1,576 2,361 49.81
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 0 24,931 0 91
2018-05-11 13F-HR Cutter & CO Brokerage, Inc. 48,175 50,743 5.33 132 185 40.15
2018-05-10 13F-HR Ford Financial Group, Inc. 6,925 0 -100.00 19 0 -100.00
2018-04-30 13F-HR TCI Wealth Advisors, Inc. 324 324 0.00 1 1 0.00
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 1,187 808 -31.93 3 3 0.00
2018-05-03 13F-HR Carnick & Kubik Group, LLC 44,638 44,638 0.00 123 163 32.52
2018-05-15 13F-HR STATE STREET CORP 0 16,900 0 62
2018-05-09 13F-HR FEDERATED INVESTORS INC /PA/ 764 683 -10.60 2 2 0.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 12,438 20,513 64.92 34 75 120.59
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 906 30 -96.69 2 0 -100.00
2018-05-09 13F-HR IFP Advisors, Inc 23,612 23,612 0.00 65 86 32.31
2018-05-15 13F-HR ELEMENT CAPITAL MANAGEMENT LLC 71,812 0 -100.00 197 0 -100.00
2018-05-15 13F-HR BlueCrest Capital Management Ltd 31,232 114
2018-05-15 13F-HR DEUTSCHE BANK AG\ 220 2,326 957.27 0 8
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 146,737 302,374 106.07 404 1,104 173.27
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 29,521 20,607 -30.20 81 75 -7.41
2018-05-10 13F-HR Stratos Wealth Partners, LTD. 77 77 0.00 0 0
2018-04-20 13F-HR FIRST QUADRANT L P/CA 13,135 0 -100.00 36 0 -100.00
2018-05-08 13F-HR US BANCORP \DE\ 4,155 4,155 0.00 11 15 36.36
2018-05-01 13F-HR WEDBUSH SECURITIES INC 10,000 10,000 0.00 28 37 32.14

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

BRIEF-Erin Energy Corporation Announces Restructuring Filing

2018-04-26 reuters
* FILED VOLUNTARY PETITIONS UNDER CHAPTER 11 OF THE UNITED STATES CODE IN THE UNITED STATES BANKRUPTCY COURT (2-1)

Erin Energy's (ERN) CEO Femi Ayoade on Q4 2017 Results - Earnings Call Transcript

2018-03-16 seekingalpha
Erin Energy Corp. (NYSEMKT:ERN) Q4 2017 Results Earnings Conference Call March 16, 2018 11:00 AM ET (2-0)

BRIEF-Erin Energy Responds To Media Reports Regarding Oyo Field Operations

2018-03-15 reuters
* ERIN ENERGY - MEDIA REPORTS “ERRONEOUSLY CONTENDED” THAT A NIGERIAN COURT ORDERED “TAKE OVER” OF OYO OIL FIELD Source text for Eikon: Further company coverage: (2-0)

CUSIP: 295625107